Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Gonadorelin (GnRH)

Gonadotropin-releasing hormone (GnRH) analog10 amino acidsBrand: Factrel, Lutrepulse, HRF

AFDA Approved
95
Excellent Credibility
3 cited studies | Evidence level A

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous decapeptide produced in the hypothalamus. It is FDA-approved for diagnosing hypothalamic-pituitary-gonadal axis function, treating primary hypothalamic amenorrhea, and triggering ovulation in fertility protocols. It acts as a GnRH receptor agonist, stimulating the pituitary to release LH and FSH.

Mechanism of Action

Binds to and activates GnRH receptors (GnRHR) on pituitary gonadotroph cells. Pulsatile administration stimulates gonadotropin release (LH and FSH), which drives gonadal steroidogenesis and gametogenesis. Continuous administration paradoxically suppresses the HPG axis via receptor desensitization. Unlike modified GnRH agonists (leuprolide, triptorelin), native gonadorelin has a short half-life (~2–4 minutes) and is used specifically for pulsatile therapy or diagnostic testing.

Benefits

  • FDA-approved for diagnosis of hypothalamic-pituitary-gonadal dysfunction[2]
  • Pulsatile gonadorelin therapy restores ovulation in hypothalamic amenorrhea — Lancet reviewed[1]
  • Used as ovulation trigger in IVF protocols — included in Cochrane network meta-analyses[3]
  • Derivative GnRH antagonists are standard treatment for endometriosis and uterine fibroids[2]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Gonadorelin (GnRH) - Dosing in Published Research

Reported routes: Subcutaneous injection, Intravenous infusion, Intravenous bolus
Pulsatile therapy: 5–20 μg per pulse every 60–90 minutes via subcutaneous or intravenous pump (Lutrepulse system). Diagnostic use: 100 μg single subcutaneous or intravenous dose, measuring LH response at 15–60 minutes. As a GnRH agonist trigger in IVF: dosage varies by protocol. Requires precise pulsatile delivery to be effective — continuous administration suppresses the axis.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Well-characterized safety profile from decades of clinical use[1]
  • Pulsatile therapy: generally well-tolerated; injection site reactions possible[1]
  • Continuous therapy: initial flare effect (temporary hormone surge) followed by suppression[1]
  • Continuous therapy may cause menopausal-like symptoms (hot flashes, vaginal dryness)[2]

Discuss Gonadorelin (GnRH) with a doctor

Gonadorelin (GnRH) is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Explore Free Tools

Provider matching is not live in this market yet.

FDA approvedBoard-certified doctorsPrescription if appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Gonadorelin (GnRH) in PeptideScholar's approved-treatment dataset

Gonadorelin (GnRH) is currently modeled on this site as an approved treatment path for: Diagnosis of HPG axis function; primary hypothalamic amenorrhea (pulsatile therapy). Brand names in the current dataset: Factrel, Lutrepulse, HRF.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

Research & Evidence

References

  1. 1.Gonadotropin-releasing-hormone-receptor antagonists.. Lancet, 2001. "Lancet review of GnRH receptor antagonists, establishing the clinical foundation for GnRH-based therapies in reproductive medicine" [PMID: 11734258]
  2. 2.Medical management of endometriosis.. Curr Opin Obstet Gynecol, 2024. "Review confirming GnRH agonists/antagonists as first-line medical therapy for endometriosis" [PMID: 39159261]
  3. 3.Triggering oocyte maturation in IVF treatment in healthy responders: a systematic review and network meta-analysis.. Fertil Steril, 2025. "Network meta-analysis including GnRH agonist triggers in IVF, confirming efficacy for oocyte maturation" [PMID: 39547644]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Wellness Support Products

Tools and supplements that support overall health and vitality.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Gonadorelin (GnRH) FAQ